A monthly two - drug injection of cabotegravir and rilpivirine to control HIV is a step closer after a second trial by pharmaceutical company GlaxoSmithKline ( GSK ) . It confirmed an earlier report which had suggested the injection was as effective as the established regime of three daily doses . HIV ’s majority - owned HIV division ViiV Healthcare said the injection could transform HIV treatment by cutting the number of treatment options from 365 to 12 . ViiV , also owned by Pfizer and Shionogi , hopes the development will let it compete with US firm Gilead Sciences , which currently dominates the $ 500 - a - year HIV sector .
A monthly two-drug injection of cabotegravir and rilpivirine to control HIV is a step closer after a second study by pharmaceutical company GlaxoSmithKline (GSK). It confirmed an earlier test which had suggested the injection was as effective as the established regime of three daily pills. GSK’s majority-owned HIV division ViiV Healthcare said the injection could transform HIV treatment by cutting the number of treatment days from 365 to 12. ViiV, also owned by Pfizer and Shionogi, hopes the development will let it compete with US firm Gilead Sciences, which currently dominates the $26bn-a-year HIV sector.